Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGV-001 in Newly Diagnosed Glioblastoma
NCT04485949Phase 2Active, not recruiting
- Sponsor
- Imvax
- Start
- Mar 2023
- Primary completion
- Jan 2027
- Modality
- Whole Cell Cancer Vaccines, Device-based Delivery, Modified DNA Oligonucleotides
- Countries
- 1
01
Overview
A Phase 2 trial of IGV-001 in glioblastoma (GBM), sponsored by Imvax. Started Mar 2023; status: active, not recruiting.
02
Drugs
IGV-001
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04485949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485949.